MCM
BBIO icon

Manchester Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Manchester Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-253
Closed -$4K – 1029
2021
Q4 		$4K Hold
253
– – ﹤0.01% 704
2021
Q3 		$12K Buy
+253
New +$13.6K ﹤0.01% 567

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Manchester Capital Management's BBIO Position: Q1 2022 in Review

Manchester Capital Management sold out of BridgeBio Pharma (BBIO) in Q1 2022, closing a stake of 253 shares — an estimated $4K sold.

Manchester Capital Management first reported a position in BBIO in Q3 2021 and held it in 2 quarters. The position peaked at $12K in Q3 2021. 178 funds tracked by Wall St. Rank hold BBIO as of Q1 2022.

  • Manchester Capital Management reported no remaining BridgeBio Pharma position as of Q1 2022 after selling out during the quarter.
  • Manchester Capital Management sold 253 BridgeBio Pharma shares in Q1 2022, an estimated $4K.
  • Manchester Capital Management first reported a position in BridgeBio Pharma in Q3 2021 and held it in 2 quarters.
  • Manchester Capital Management's BridgeBio Pharma position peaked at $12K in Q3 2021.
  • 178 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2022.

Based on Manchester Capital Management's 13F filing for Q1 2022, filed 9 May 2022.